European Healthcare Regulator has recommended the conditional approval of remdesivir to use for Coronavirus Patients
According to The European Healthcare Regulator it has recommended the conditional approval of the Gilead’s Antiviral Treatment, remdesivir, to use for Coronavirus patients, this is the first treatment that is on track to be approved in the EU.
According to the European Medicines Agency (EMA) on Thursday, its human medicines committee (CHMP) recommended the remdesivir, to use in adults and adolescents from 12 years of age with pneumonia who require oxygen support.
The price of the remidesivir is not yet known. Rumors in the United States are that the price could be estimated at 5,000 USD per course, while Indian Generic drug-makers estimated the price between 5,000 rupees and 6,000 rupees that’s between 60 – 80 USD.
The EMA endorsement, which comes just weeks after a rapid reviews, means physicians can prescribe the Gilead Drug (remdesivir), to be branded as Veklury, in Europe once approved by the European Commission, which usually follows CHMP recommendations.
The EU’s Conditional marketing authorization allows a treatment to be sold for a year in the 27 nation trading bloc before all necessary data on its efficacy and side-effects are available. Gilead (Remdesivir) has to submit final data by December.
The demand for the drug decreased after it became the frontrunner following promise in trails. The supply of the remdesivir to could exceed 2 million courses by end of the year. That is double the target as previous expected.
Remdesivir has already been approved to use on critical patients in the U.S, India, South Korea, and Japan